Compare · IMDX vs LMDX
IMDX vs LMDX
Side-by-side comparison of Insight Molecular Diagnostics Inc. (IMDX) and LumiraDx Limited (LMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMDX and LMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX is the larger of the two at $2.23B, about 12.8x IMDX ($174.4M).
- IMDX has hit the wire 8 times in the past 4 weeks while LMDX has been quiet.
- LMDX has more recent analyst coverage (4 ratings vs 0 for IMDX).
- Company
- Insight Molecular Diagnostics Inc.
- LumiraDx Limited
- Price
- $5.35-1.83%
- $0.02-53.80%
- Market cap
- $174.4M
- $2.23B
- 1M return
- -13.50%
- -
- 1Y return
- +42.86%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 0
- 4
Latest IMDX
- iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
- Director Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)
- Director Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)
- Director Arno Andrew was granted 32,331 shares, increasing direct ownership by 24% to 168,885 units (SEC Form 4)
- IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
- iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
- SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points